Related Experiment Video
Updated: Sep 20, 2025
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
11β-HSD1 Inhibitor Alleviates Non-Alcoholic Fatty Liver Disease by Activating the AMPK/SIRT1 Signaling Pathway
Ying Chen1, Jiali Li1, Meng Zhang1
1Heilongjiang Key Laboratory of Tissue Damage and Repair, College of Life Science, Mudanjiang Medical University, Mudanjiang 157011, China.
Abstract:
We investigated the effect of an 11β-HSD1 inhibitor (H8) on hepatic steatosis and its mechanism of action. Although H8, a curcumin derivative, has been shown to alleviate insulin resistance, its effect on non-alcoholic fatty liver disease (NAFLD) remains unknown. Rats were fed a high-fat diet (HFD) for 8 weeks, intraperitoneally injected with streptozotocin (STZ) to induce NAFLD, and, then, treated with H8 (3 or 6 mg/kg/day) or curcumin (6 mg/kg/day) for 4 weeks, to evaluate the effects of H8 on NAFLD. H8 significantly alleviated HFD+STZ-induced lipid accumulation, fibrosis, and inflammation as well as improved liver function. Moreover, 11β-HSD1 overexpression was established by transfecting animals and HepG2 cells with lentivirus, carrying the 11β-HSD1 gene, to confirm that H8 improved NAFLD, by reducing 11β-HSD1. An AMP-activated protein kinase (AMPK) inhibitor (Compound C, 10 μM for 2 h) was used to confirm that H8 increased AMPK, by inhibiting 11β-HSD1, thereby restoring lipid metabolic homeostasis. A silencing-related enzyme 1 (SIRT1) inhibitor (EX572, 10 μM for 4 h) and a SIRT1 activator (SRT1720, 1 μM for 4 h) were used to confirm that H8 exerted anti-inflammatory effects, by elevating SIRT1 expression. Our findings demonstrate that H8 alleviates hepatic steatosis, by inhibiting 11β-HSD1, which activates the AMPK/SIRT1 signaling pathway.
Insights
H8, an 11β-HSD1 inhibitor, effectively treats non-alcoholic fatty liver disease (NAFLD) by reducing liver fat, fibrosis, and inflammation. It works by activating the AMPK/SIRT1 pathway, offering a new therapeutic approach for NAFLD.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Non-alcoholic fatty liver disease (NAFLD) is a growing health concern with limited treatment options.
- The enzyme 11β-HSD1 plays a crucial role in hepatic lipid metabolism and NAFLD pathogenesis.
- H8, a curcumin derivative, is a known inhibitor of 11β-HSD1, but its efficacy in NAFLD is unexplored.
Purpose of the Study:
- To investigate the therapeutic effect of H8 on hepatic steatosis in a rat model of NAFLD.
- To elucidate the underlying molecular mechanisms by which H8 ameliorates NAFLD.
Main Methods:
- NAFLD was induced in rats using a high-fat diet (HFD) and streptozotocin (STZ) injection.
- Rats were treated with H8 (3 or 6 mg/kg/day) or curcumin (6 mg/kg/day) for 4 weeks.
- In vitro studies using HepG2 cells and in vivo experiments with lentiviral gene delivery were performed to confirm the role of 11β-HSD1.
- Involvement of AMP-activated protein kinase (AMPK) and Sirtuin 1 (SIRT1) pathways was assessed using specific inhibitors and activators.
Main Results:
- H8 treatment significantly reduced lipid accumulation, fibrosis, and inflammation in the livers of HFD+STZ-fed rats.
- H8 administration improved overall liver function and alleviated NAFLD markers.
- The beneficial effects of H8 were attributed to the inhibition of 11β-HSD1, leading to activation of the AMPK/SIRT1 signaling pathway.
Conclusions:
- H8 demonstrates significant therapeutic potential for treating NAFLD by targeting hepatic 11β-HSD1.
- H8 alleviates hepatic steatosis through the activation of the AMPK/SIRT1 signaling cascade.
- These findings suggest H8 as a promising candidate for NAFLD treatment.
More Related Videos
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
